Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

MET is a driver oncogene in non-small-cell lung cancer (NSCLC), and its amplification is associated with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A 56-year-old Japanese male with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation received e...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Respir Med Case Rep
मुख्य लेखकों: Yoshimura, Katsuhiro, Inui, Naoki, Karayama, Masato, Inoue, Yusuke, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Takeuchi, Kengo, Sugimura, Haruhiko, Suda, Takafumi
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Elsevier 2017
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5322209/
https://ncbi.nlm.nih.gov/pubmed/28271038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.02.009
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन